This evaluation investigated the cost‐effectiveness of pembrolizumab plus chemotherapy using PD‐L1 test to select Pembro‐chemotherapy combination therapy for patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutation in the United States and China. The gene discussed is ALK; the disease is non-small cell lung carcinoma.